Best Strategies for Hypertension Management in Type 2 Diabetes and Obesity

Telmisartan, ramipril, or both in patients at high risk for vascular events

(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502 · see citing works

Treatment of hypertension in patients 80 years of age or older

Beckett, N. S., Peters, R., Fletcher, A. E., Staessen, J. A., Liu, L., Dumitrascu, D., Stoyanovsky, V., Antikainen, R. L., Nikitin, Y., Anderson, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801369 · Cited by 3,092 · see citing works

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471 · see citing works

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

Jamerson, K., Weber, M. A., Bakris, G. L., Dahlöf, B., Pitt, B., Shi, V., Hester, A., Gupte, J., Gatlin, M., & Velazquez, E. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806182 · Cited by 2,065 · see citing works

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

Hansson, L., Lindholm, L. H., NISKANEN, L. K., Lanke, J., Hedner, T., Niklason, A., LUOMANMÄKI, K., Dahlöf, B., Fairé, U. D., Mörlin, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)05012-0 · Cited by 1,991 · see citing works

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39

Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B., et al. (1998) · BMJ · doi:10.1136/bmj.317.7160.713 · Cited by 1,784 · see citing works

Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560 · see citing works

Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2000) · JAMA · doi:10.1001/jama.283.15.1967 · Cited by 1,553 · see citing works

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39

Stearne, M. R., Palmer, S. L., Hammersley, M. S., Franklin, S. L., Spivey, R. S., Lévy, J., Tidy, C. R., Bell, N. J., Steemson, J., Barrow, B. A., et al. (1998) · UCL Discovery (University College London) · Cited by 1,406 · see citing works

A Comparison of Outcomes with Angiotensin-Converting–Enzyme Inhibitors and Diuretics for Hypertension in the Elderly

Wing, L. M. H., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L. R., Johnston, C. I., McNeil, J. J., Macdonald, G. J., Marley, J. E., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021716 · Cited by 1,130 · see citing works

Effect of Ramipril vs Amlodipine on Renal Outcomes in Hypertensive Nephrosclerosis A Randomized Controlled Trial

Agodoa, L. Y. C. (2001) · JAMA · doi:10.1001/jama.285.21.2719 · Cited by 935 · see citing works

Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study

Hansson, L., Hedner, T., Lund‐Johansen, P., Kjeldsen, S. E., Lindholm, L. H., Syvertsen, J. O., Lanke, J., Fairé, U. D., Dahlöf, B., & Karlberg, B. E. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02526-5 · Cited by 903 · see citing works

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes

Chaturvedi, N., Sjolie, A.-K., Stephenson, J., Abrahamian, H., Keipes, M., Castellarin, A., Rogulja-Pepeonik, Ž., & Fuller, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)06209-0 · Cited by 738 · see citing works

Reduction of Cardiovascular Risk by Regression of Electrocardiographic Markers of Left Ventricular Hypertrophy by the Angiotensin-Converting Enzyme Inhibitor Ramipril

Mathew, J., Sleight, P., Lonn, E., Johnstone, D. E., Pogue, J., Yi, Q., Bosch, J., Sussex, B. A., Probstfield, J. L., & Yusuf, S. (2001) · Circulation · doi:10.1161/hc3901.096700 · Cited by 555 · see citing works

Ramipril and the Development of Diabetes

Yusuf, S. (2001) · JAMA · doi:10.1001/jama.286.15.1882 · Cited by 541 · see citing works

Comparative Antihypertensive Effects of Hydrochlorothiazide and Chlorthalidone on Ambulatory and Office Blood Pressure

Ernst, M. E., Carter, B. L., Goerdt, C. J., Steffensmeier, J. J. G., Phillips, B. B., Zimmerman, M. B., & Bergus, G. R. (2006) · Hypertension · doi:10.1161/01.hyp.0000203309.07140.d3 · Cited by 433 · see citing works

Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy

Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International · doi:10.1038/ki.1996.480 · Cited by 417 · see citing works

Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group.

(2000) · PubMed · Cited by 389 · see citing works

Narrative Review: The Emerging Clinical Implications of the Role of Aldosterone in the Metabolic Syndrome and Resistant Hypertension

Sowers, J. R., Whaley-Connell, A., & Epstein, M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-11-200906020-00005 · Cited by 351 · see citing works

A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial

Weber, M. A., Black, H. R., Bakris, G. L., Krum, H., Linas, S. L., Weiss, R., Linseman, J. V., Wiens, B. L., Warren, M. S., & Lindholm, L. H. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61500-2 · Cited by 332 · see citing works

Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy

Solomon, S. D., Appelbaum, E. A., Manning, W. J., Verma, A. K., Berglund, T., Lukashevich, V., Papst, C. C., Smith, B. A., & Dahlöf, B. (2009) · Circulation · doi:10.1161/circulationaha.108.826214 · Cited by 301 · see citing works

Fasting Glucose Levels and Incident Diabetes Mellitus in Older Nondiabetic Adults Randomized to Receive 3 Different Classes of Antihypertensive Treatment

Barzilay, J. I. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.20.2191 · Cited by 264 · see citing works

Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients

Lindholm, L. H., Hansson, L., Ekbom, T., Dahlöf, B., Lanke, J., Linjer, E., Scherstéln, B., Wester, P. O., Hedner, T., & Fairé, U. D. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018110-00020 · Cited by 198 · see citing works

A comparison of atenolol and nebivolol in isolated systolic hypertension

Dhakam, Z., Yasmin, Y., McEniery, C. M., Burton, T., Brown, M. J., & Wilkinson, I. B. (2008) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f283c9 · Cited by 195 · see citing works

Telmisartan, Ramipril, or Both in Patients at High Risk of Vascular Events

Büchner, N., Banas, B., & Krämer, B. K. (2008) · New England Journal of Medicine · doi:10.1056/nejmc081065 · Cited by 175 · see citing works

Low-dose spironolactone in the management of resistant hypertension: a surveillance study

Lane, D. A., Shah, S., & Beevers, D. G. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e328014954d · Cited by 137 · see citing works

Long-Term Antihypertensive Efficacy and Safety of the Oral Direct Renin Inhibitor Aliskiren

Schmieder, R. E., Philipp, T., Guerediaga, J., Gorostidi, M., Smith, B. A., Weissbach, N., Maboudian, M., Botha, J., & van Ingen, H. (2009) · Circulation · doi:10.1161/circulationaha.107.750745 · Cited by 132 · see citing works

Aliskiren Enhances the Protective Effects of Valsartan Against Cardiovascular and Renal Injury in Endothelial Nitric Oxide Synthase–Deficient Mice

Yamamoto, E., Kataoka, K., Dong, Y., Nakamura, T., Fukuda, M., Tokutomi, Y., Matsuba, S., Nako, H., Nakagata, N., Kaneko, T., et al. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133884 · Cited by 66 · see citing works

ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update

Bakris, G. L., Sowers, J. R., & on behalf of the American Society of Hypertension Writing Group (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00012.x · Cited by 61 · see citing works

Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, double-blind trial

Schmieder, R. E., Philipp, T., Guerediaga, J., Gorostidi, M., Bush, C. A., & Keefe, D. L. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32832be593 · Cited by 49 · see citing works

Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism

Pessina, A. C., Ciccariello, L., Perrone, F., Stoico, V., Gussoni, G., Scotti, A., & Muggeo, M. (2005) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2005.04.005 · Cited by 45 · see citing works

Nebivolol decreases endothelial cell stiffness via the estrogen receptor beta: a nano-imaging study

Hillebrand, U., Lang, D., Telgmann, R., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e32831fb389 · Cited by 26 · see citing works

Possible Involvement of Akt Activity in Endothelial Dysfunction in Type 2 Diabetic Mice

Takenouchi, Y., Kobayashi, T., Matsumoto, T., & Kamata, K. (2008) · Journal of Pharmacological Sciences · doi:10.1254/jphs.fp0071684 · Cited by 20 · see citing works

Initial Combination Therapy Compared With Monotherapy in Diabetic Hypertensive Patients

Sowers, J. R., Lastra, G., Rocha, R., Seifu, Y., Crikelair, N., & Levy, D. G. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.00003.x · Cited by 12 · see citing works

Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of <i>The Obesity Society</i> and the <i>American Society of Hypertension</i>

Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528 · see citing works

The comparison between combination of candesartan-amlodipine and candesartan-furosemide on blood pressure in hypertensive patients with chronic kidney disease

Rachmaini, F., Juwita, D. A., Almahdy, A., Abdillah, R., & Wati, Y. M. (2022) · Pharmaciana · doi:10.12928/pharmaciana.v12i2.21491 · Cited by 3 · see citing works

Genetic Background (C57BL/6J Versus FVB/N) Strongly Influences the Severity of Diabetes and Insulin Resistance in ob/ob Mice

Haluzı́k, M., Colombo, C., Gavrilova, O., Chua, S. C., Wolf, N., Chen, M., STANNARD, B. S., Dietz, K. R., Roith, D. L., & Reitman, M. L. (2004) · Endocrinology · doi:10.1210/en.2004-0219 · Cited by 180 · see citing works

Peroxisome Proliferator-Activated Receptor-α Deficiency Does Not Alter Insulin Sensitivity in Mice Maintained on Regular or High-Fat Diet: Hyperinsulinemic-Euglycemic Clamp Studies

Haluzı́k, M., Gavrilova, O., & LeRoith, D. (2003) · Endocrinology · doi:10.1210/en.2003-1015 · Cited by 39 · see citing works

Chronic hyperinsulinemia contributes to insulin resistance under dietary restriction in association with altered lipid metabolism in Zucker diabetic fatty rats

Morita, I., Tanimoto, K., Akiyama, N., Naya, N., Fujieda, K., Iwasaki, T., & Yukioka, H. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00342.2016 · Cited by 19 · see citing works

Effect of short-and long-term caloric restriction on insulin resistance in male fisher-344 rats

Shu, C., Rusen, C., & Leakey, J. (1996) · Zhonghua neifenmi daixie zazhi